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Abstract: There is growing awareness for the need of early diagnostic tools to aid in point-of-care
testing in cancer. Tumor biopsy remains the conventional means in which to sample a tumor and often
presents with challenges and associated risks. Therefore, alternative sources of tumor biomarkers is
needed. Liquid biopsy has gained attention due to its non-invasive sampling of tumor tissue and
ability to serially assess disease via a simple blood draw over the course of treatment. Among the
leading technologies developing liquid biopsy solutions, microfluidics has recently come to the fore.
Microfluidic platforms offer cellular separation and analysis platforms that allow for high throughout,
high sensitivity and specificity, low sample volumes and reagent costs and precise liquid controlling
capabilities. These characteristics make microfluidic technology a promising tool in separating and
analyzing circulating tumor biomarkers for diagnosis, prognosis and monitoring. In this review,
the characteristics of three kinds of circulating tumor markers will be described in the context of
cancer, circulating tumor cells (CTCs), exosomes, and circulating tumor DNA (ctDNA). The review
will focus on how the introduction of microfluidic technologies has improved the separation and
analysis of these circulating tumor markers.
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1. Introduction
The rapid development of cancer biomarker technologies is gradually reshaping both the
academic and clinical research areas. As we step into the age of personalised medicine, the need
for comprehensive cancer biomarkers has dramatically increased [1]. This was evidenced at the
recent American Society for Clinical Oncology (ASCO) 2018 and American Association for Cancer
Research (AACR) 2018. Cancer related deaths still remain the second leading cause of non-accidental
deaths globally [2]. There is an increasing number of technologies being developed for pre-screening,
diagnostic, prognostic, therapy assessment, and monitoring of disease. The progression free survival
(PFS) and overall survival (OS) in cancer patients has been reported to be dramatically increased if
cancers can be detected at an early stage [3].
To date, there are several forms of direct tumor biopsy. According to the tumor site, bone
marrow biopsy, endoscopic biopsy, needle biopsies, and skin biopsy will be performed by clinicians
in direct assessment of the tumor bulk. In most cases of solid tumors, an image-assisted core needle
biopsy is performed, using needles to extract a column of tissue, followed by tissue interrogation
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by histopathologists [4]. Tissue biopsy remains the gold standard when diagnosing cancer [5].
To determine whether the abnormal tissue is malignant, clinicians have to perform invasive procedures
to obtain a small portion of tumor tissue which is later confirmed by histopathology, cytology,
and molecular/cytogenetically. It is currently the only way of validating whether the suspicious
tissue is cancerous, and can be an invasive procedure for patients to endure [6]. In some cases, it has
been reported that the procedure may induce risk of bleeding, inflammation, and even dissemination
of cancer cells by providing alternative routes for spreading [7]. Furthermore, repeat tissue biopsy is
not always a possibility. Therefore, traditional tumor biopsy only provides a static tumoral snapshot
of a specific time point, and does not reflect dynamic changes that occur during cancer treatment [8].
Moreover, the time-to-result procedure takes several days and sometimes weeks to reach clinicians [9].
A study assessing the patient outcomes and the economic implications of utilizes a serum proteomic
test to guide the treatment in non-small cell lung cancer. It shows that the blood test resulted in an
improved OS rate along with the total lifetime, and the direct medical cost decreased by $135 (U.S.
dollars) per patient with test-guided treatment [10]. Tumor heterogeneity is an added challenge with
tumor biopsy. Sampling a tumor using a single site biopsy is akin to looking through a keyhole [11,12].
Therefore, the tumor samples obtained by needle biopsy may only represent a small proportion of the
whole tumor, which leads to an over estimation of the clonal populations in the tumor bulk. Liquid
biopsy may overcome the disadvantages of conventional tumor biopsy methods. Circulating tumor
cells (CTCs), circulating tumor DNA (ctDNA) and exosomes which are easily assessable by a simple
blood draw, present an attractive alternative to tissue biopsies, and may represent the primary and
metastatic tumor sites [13].
As a result of highly sensitive assays and innovative detection platforms, the promise of a liquid
biopsy is now closer to reality [14]. Compared to conventional tissue biopsy, a liquid biopsy offers
a multi-parameter approach to assess targets for therapy on CTCs, cell-free ctDNA, and exosomes
secreted from tumors during the metastatic process [5]. Blood sampling is a non-invasive process and
it avoids the complications of traditional tissue biopsies. Liquid biopsy provides an alternative sample
type for routine clinical practice when tumor sampling is unavailable, inappropriate, or difficult to
obtain. Moreover, it may be possible to assess the dynamic tumoral changes via CTCs and ctDNA
over the course of therapy and when treatment resistance becomes a challenge. The analysis of liquid
biopsy could be used to provide early cues into alternate therapies before the tumor relapse is detected
by conventional methods [13]. To this end, microfluidic technologies have come to the fore in the last
few years, where the convenience of such technologies is surpassing that of conventional laboratory
bench techniques, such as flow cytometry. Microfluidics provide miniaturized devices that offer fast
isolation speeds with high efficiencies and automation, which can be integrated rapidly into multiple
workflows [15]. The microfluidic technologies have numerous advantages over conventional methods
by reducing the size of equipment, eliminating complex protocols for cell sorting, and allowing for
parallelization, which can enable complete lab-on-a-chip devices [16].
Remarkable progress has been achieved in the last decade in the field of microfluidics, leading to
applications in single cell analysis and next-generation sequencing technology. With these technological
advances, applications have been found for liquid biopsy, which have been reviewed recently [17–19],
particularly in context of device operation and modalities for CTC sorting. In this review, our intention is
to focus more on recent clinical works, and to further highlight the emerging role of microfluidics in order
to capture and detect the circulating biomarkers (CTCs, ctDNA, and exosomes), with a focus on the most
analytically valid systems. Furthermore, this review provides insight into how microfluidic technologies
can be implemented into existing clinical workflows, providing a personalized medicine approach.
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2. Circulating Biomarkers in Liquid Biopsy. Molecular, Biology, and Morphology Characteristics
of CTC, ctDNA, and Exosomes
2.1. Circulating Tumor Cells (CTCs)
Circulating tumor cells were first observed by Thomas Ashworth, an Australian physician,
who made the incredible finding that cells identical to the tumor itself were found in the blood of a
patient with metastatic disease [20].Since this discovery, the field remained in its infancy until about
the last 20 years, where there has been an exponential increase in CTC research. This is primarily due
to the improvements in rare cell capture from the blood. As of August 2015, there have been 16,688
publications reported on CTCs, 1248 of these were published in 2014, reflecting the advancement of the
field over recent years. With the advent of the CellSearch (Menarini-Silicon Biosystems, Bologna, Italy),
the first and only Food and Drug Administration (FDA) approved CTC enrichment and enumeration
technology came to the clinical setting. In the CellSearch platform, preselected tumor cells for epithelial
cell adhesion molecules (EpCAM) and EpCAM-positive CTCs were found to correlate to clinical
outcomes. The CTC thresholds were established where five or more CTCs/7.5 mL blood for breast and
prostate, and three or more CTCs/7.5 mL blood draw for colorectal cancer were associated with an
unfavorable patient prognosis [21]. These findings coined the term ‘liquid-biopsy’, where CTCs could
be used to determine the tumorigenic potential non-invasively [22]. Whilst enumeration by CellSearch
correlated to the clinical outcomes, numerous limitations were found with the technology. There was
a drive to investigate beyond the simple enumeration of CTCs. Moreover, EpCAM was shown to
be downregulated in the CTCs during the process of epithelial to mesenchymal transition (EMT),
as reported by Yu et al. [23]. The bottle neck in the field was to increase the number of rare CTCs
isolated from a blood sample, as there was an increased demand for intact, live CTCs with which to
perform a functional analysis. This was overcome by a number of leading research groups by utilising
in vivo and ex vivo culture methodologies [24–26]. Subsequently, this increase in the critical mass of
the CTCs provided the foundation for the testing of therapies outside the patients’ body [25,26].
2.2. Monitoring of Disease
CTCs have been reported to not only be useful prior to treatment, but also over the course of
therapy [23]. The ability to non-invasively sample a patient’s tumor by a simple blood draw during
treatment provides an attractive solution for disease monitoring (Figure 1). Generally, a decrease in the
CTC-numbers (disease burden) has been shown to correspond to better treatment outcomes, and the
absence of CTCs post therapy provide a good patient prognosis [21]. Yu et al., 2013, demonstrated
in breast cancer that in sequential blood draws from the same patient over the course of therapy,
a mesenchymally-shifted CTC population was present post therapy. Therefore, a subset of CTCs
with an altered phenotype may remain post treatment. Numerous studies have documented the
persistence of stem-like CTCs and mesenchymal CTCs post treatment [27]. Therefore, it becomes
critical to profile these residual CTC populations, which may underline the minimal residual disease
in patients following therapy.
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selection technologies such as the CellSearch. Therefore, there is an understanding that multi-epitope 
CTC capture is required to capture the CTC subpopulations at play [30]. Moreover, it has been shown 
that individual cytokeratin expression is often downregulated during EMT, and a pan-keratin 
cocktail enables the tracking of partially lost epithelial phenotypes [31,32]. In understanding this 
biological process, numerous groups around the world moved towards a marker-independent CTC 
enrichment to capture a greater proportion of CTCs in circulation [33–35]. These studies 
demonstrated that higher numbers of CTCs were captured using label-free methodologies as well as 
in head to head comparisons with the CellSearch platform, showed higher CTC capture in lung, 
breast and head and neck cancers [36,37] It is important to note that whilst higher CTC counts are 
detected by label-free capture, for most cases, it is only the EpCAM-positive CTCs that have 
demonstrated clinical significance to date. 
2.4. Biomarkers for Immunotherapy 
More recently, immunotherapies have been shown to have durable responses and long-term 
survival outcomes in a number of tumor types, including melanoma, head and neck, and non-small 
cell lung cancer [38–40]. Immunotherapies such as anti PD-1/PD-L1 have shown highly variable 
tumoral scoring for eligibility onto PD-1/PD-L1 trials. Studies have shown this to be due to multiple 
reasons, including tumoral heterogeneity and the dynamic nature of PD-1/PD-L1. Therefore, 
alternative methods of surveying the PD-1/PD-L1 landscape are needed. Mazel et al., 2015, 
demonstrated, in a landmark study, the presence of PD-L1 on breast CTCs, and developed a scoring 
mechanism. In keeping with this, the CellSearch platform has been further developed to include a 
PD-L1 stain in the blank channel to further characterise EpCAM-positive CTCs. The PD-L1 is 
Figure 1. Clinical applications of liquid biopsy from blood circulating markers. The genomics and
immunology information derived from liquid biopsy samples can be used for continuous monitoring,
from early stage disease screening, assistance diagnosis, personalized therapy selection, to recurrence
monitoring. CTC—circulating tumor cells; ctDNA—circulating tumor DNA.
2.3. Epithelial to Mesenchymal Transition (EMT)
Whilst found to occur in embryologic development, gastrulation, and cell plasticity roles, EMT
is known to be involved in the process of metastasis. During this process, cancer cells are thought
to undergo an epithelial to mesenchymal transition (EMT); down regulate epithelial markers such
as EpCAM and E-cadherin [28,29]; lose cell–cell adhesion properties; and become more invasive
towards a mesenchymally-s ifted phenotype expressing markers such as Vimentin and N-Cadherin.
In attaining a partial o complete EMT, TCs would inherently be missed by epithelial marker
selection technologies such as the C llSearch. Theref re, there is an understandi g that multi-epitope
CTC capture is required to capture the CTC subpopulations at play [30]. Moreover, it has been
shown that individual cytokeratin expression is often downregulated during EMT, and a pan-keratin
cocktail enables the tracking of partially lost epithelial phenotypes [31,32]. In understanding this
biological process, numerous groups around the world moved towards a marker-independent CTC
enrichment to capture a greater proportion of CTCs in circulation [33–35]. These studies demonstrated
that higher numbers of CTCs were captured using label-free methodologies as well as in head to
head co parisons with the CellSearch platform, showed higher CTC capture in lung, breast and
head and neck cancers [36,37] It is important to note that whilst higher CTC counts are detected by
label-free capture, for ost cases, it is only the EpCAM-positive CTCs that have demonstrated clinical
significance to dat .
2.4. Biomarkers for Immunotherapy
More recently, immunotherapies have been shown to have durable responses and long-term
survival outcomes in a number of tumor types, including melanoma, head and neck, and non-small cell
lung cancer [38–40]. Immunotherapies such as anti PD-1/PD-L1 have shown highly variable tumoral
scoring for eligibility onto PD-1/PD-L1 trials. Studies have shown this to be due to multiple reasons,
including tumoral heterogeneity and the dynamic nature of PD-1/PD-L1. herefore, alternative
methods of surveying the PD-1/PD-L1 landscape are needed. Mazel et al., 2015, demonstrated,
in a landmark study, the presence of PD-L1 on breast CTCs, and developed a scoring mechanism.
In keeping with this, the CellSearch platform has been further developed to include a PD-L1 stain
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in the blank channel to further characterise EpCAM-positive CTCs. The PD-L1 is concurrently
scored against a range of known cell lines. This was further investigated in lung, and head and neck
cancers [41]; not only prior to therapy, but over the course of treatment as well [42,43]. The potential
for the development a CTC PD-L1 companion diagnostic assay is currently being investigated [44].
Notably, a recent study has shown the presence of PD-1/PD-L1 on CTCs as a result of host-immune
interactions [45]. This multitude of recent literature demonstrates the potential immune evasion
mechanisms of PD-L1 expressing CTCs.
2.5. Exosomes
Exosomes are nano-meter scale, lipid-membrane vesicles that secrete from cells and carry various
kinds of molecules such as DNA, RNA, and proteins. Unlike CTCs and ctDNA, which circulate in
the body fluid system, the lipid membranes protect biomolecules inside the exosomes. As there are
also antigens on the surface of exosomes, widely used separation methods exist that are based on
Immunoaffinity. Others methods include size differentiation and ultracentrifugation [46]. Exosomes
are a form of extracellular vesicles released by cells, typically with a size of 30–150 nm, and a lipid
bilayer. These vesicles contain RNA, DNA, and protein, and are likely to function by removing the
excess constituents from cells, and may mediate cell–cell communication [47]. In cancer, exosomes are
thought to promote tumor progression [48,49]. Exosomes have been found in numerous body fluids,
including blood, urine, amniotic fluid, tears, and breast milk [47]. Studies have demonstrated that in
lineage tracing experiments, malignant cancer cell derived exosomes when taken up by benign tumor
cells, which induces a conversion to a more malignant phenotype [50]. In metastasis, the exosomes
are thought to promote the remodelling of distant, metastasis prone organs [49]. Microfluidics have
been employed for the capture of exosomes in liquid biopsy. Numerous technologies exist, such as
the ExoSearch chip, which captures blood plasma exosomes combined with multi-marker probing for
ovarian cancer [51]. Immunoaffinity can also be utilised in microfluidics devices by manipulating the
surfaces with antibodies. Chen et al., 2010 described this using anti-CD63 functionalized surfaces [52].
The high flow rate isolation of exosomes has been shown by Dudani et al., 2015, where polystyrene
beads conjugated with anti-human CD63 were embedded in a microfluidic device that used inertial
lift forces at a finite Reynolds number in order to position microparticles, and exchanges solutions for
rapid purification [53]. To date, the standardisation of exosome isolation protocol is being developed,
from ultracentrifugation to microfluidics, and to immuno-affinity capture. Moreover, exosome specific
markers are yet to be established and markers indicative of the cell origin are needed.
2.6. ctDNA
Circulating tumor DNA is thought to be released from apoptotic tumor cells and necrotic in
circulation, and offers valuable information about tumor progression and metastasis. In doing so,
ctDNA found in body fluids can carry tumor specific genetic and epigenetic information [54,55].
Most cell-free DNA fragments are 100–200 base pairs generated from cell apoptosis. The concentration
of the cell free DNA in cancer patient are generally higher than those in healthy donors, which indicates
that the level of cell free DNA may be used for cancer screening [56]. Tumor specific mutations have
been identified in cell free DNA samples. Despite this, ctDNA still faces some challenges, such as
low ctDNA concentration, the development of allele specific amplification technologies, and high
background noise [57]. Recently, there have been landmark studies documenting how ctDNA may
be used to phylogenetically profile the subclonal nature of lung cancer relapse and metastasis [53].
Recent data has shown that tumors with a high tumor mutation burden (TMB) have a better response
to immunotherapy. This opens up avenues for the assessment of TMB via ctDNA, which is currently
being investigated to guide patients for anti PD-1/PD-L1 therapy.
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3. The Role of Microfluidics in Liquid Biopsy
Microfluidic technologies have come of age in the last 10–15 years with the efficient isolation
of tumor cells and cell derived products. Notably, microfluidic platforms offer many advantages
over conventional laboratory-based techniques, such as the low volume of samples required and
their reagents, high sensitivity, controllable and tunable flow patterns, ease of operation, low
costs and the ability to multiplex platforms. Specially, microfluidic devices can be designed to
ensure the precision of liquid manipulation, which is not possible with conventional bench-top
approaches. This advantage is crucial if low abundance cells and biomolecules are evaluated in
a homogeneous fashion. These advances enable the integration of microfluidics into cell biology,
genetics, pharmaceutics, and analytic chemistry research. In combination with serial operation units,
such as separators, mixers, reactors, and sensors, into one microfluidic chip, a streamlined experimental
process could be scaled down to nanolitre-reaction level, and provides researchers with opportunities
for analyzing the analytes both spatially and temporally. So far, the majority of microfluidic approach
focus on CTC isolation due to the rapid growing interest in cancer diagnosis.
While microfluidic techniques are promising in academic research, the barriers to
commercialization cannot be ignored. In terms of the device-related issues, microfluidic platforms that
are not integrated need to be connected manually using non-standard laboratory tools. Materials used
widely in microfluidic, such as polydimethysiloxane (PDMS), are not suitable for scaling to industrial
standards [58]. In addition, the performance of microfluidic platforms are dramatically influenced
by air bubbles and small obstructions caused by errors in the operation and the fabrication process.
Although some challenges prevent microfluidic technology from achieving its full potential, inspiring
discoveries have been shown to revolutionize how we analyze the cells and biomolecules down to
single cell level [59].
4. Circulating Tumor Cells Separation and Analysis on Microfluidic Chip
4.1. Postitive Selection of CTCs
Positive CTC selection is based on the capture of tumor cells using specific surface antigen
selection and the exclusion of normal cells. Epithelial cell adhesion molecule (EpCAM) is a widely
used marker among all of the immuno-affinity based positive selection approaches. The positive
selection of CTCs can be achieved by either coating antibodies onto the reaction channel surface, or by
artificially adding antibodies conjugated to micro particles.
4.1.1. Antibody-Coated Microstructure Separation
EpCAM coated microfluidic channel devices have been used for many years. While the blood
samples flow through the microfluidic channel, CTCs are captured against the surface of anti-EpCAM
coated microposts. The remaining blood samples are driven away from microfluidic channels.
The captured CTC samples could then be stained with fluorescence markers for enumeration purpose,
or for undergoing a genomics analysis [60]. However, the application of traditional microfluidic
channels is resisted by the small surface area for ligating antibodies, thus resulting in a limited
capture capacity. In order to overcome this limitation, various kinds of microfluidic channels have
been designed to provide more interactions between the putative CTCs and channel surfaces
(Figure 2d,e) [61,62]. Herringbone shape array, micropost array, and nanopillar array could generate a
greater surface area in the microfluidic channel, compared with the traditional designs, thus increasing
the capture efficiency of the CTCs.
NanoVelcro is a microfluidic chip with nanowires that are manufactured and coated with
anti-EpCAM antibody to identify and capture CTCs. While the blood cells flow through the chip,
the tumor cells will use immuno-affinity to stick to the nanowires like Velcro. This chip consists of
two parts, the bottom substrate is a brush-like silicon nanowire coated with an anti-EpCAM antibody,
and a PDMS herringbone structure on the top layer that generates the chaotic flow, which increases
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the contact chance between CTCs and the antibody substrate at the bottom. After the capture of CTCs,
Cytokeratin/CD45/DAPI staining is performed to identify putative CTCs on the chip (Figure 2a) [63].
Capturing the tumor cells is the first part of this platform. In the early stage of NanoVelcro
development, researchers used laser capture microdissection to cut out the areas of the CTCs and
isolate them from substrate [64]. But this method is time-consuming, and it requires highly specific
equipment and experienced operators. Now, researchers have developed thermosensitive NanoVelcro
polymer brushes, which are capable of capturing and releasing CTCs at 37 and 4 ◦C, respectively.
The NanoVelcro changes the temperature fluctuations by transforming their physical prosperities,
allowing the release of CTCs for downstream molecular assay and cell culture. Furthermore,
they fabricated polymer-based nanomaterial on chip surface, the latest NanoVelcro chip is able to
purify CTC without damaging RNA transcripts, which benefits the analysis of tumor specific RNA
markers (Figure 2a) [65].
4.1.2. In Vivo Antibody-Coated Device Capture
To overcome the restriction of limited blood volume in traditional CTC isolation methods, the
GILUPI CellColletor has been designed to collect targeted cells in vivo, by inserting the device through
a standard venous cannula into the vein of cancer patients [66]. The device is a 16 cm medical
stainless-steel wire with a 2 cm rounded tip that consists of a three-dimensional (3D) anti-EpCAM
antibody functioned layer, which comes into contact with circulating blood. Rare CTCs are bound
to the device surface by an antigen-anti-EpCAM reaction [67]. While most of the common in vitro
detection methods focus on utilizing the small volume of blood efficiently, the total volume of blood
passing the GILUPI CellColletor is estimated to be 1.5–3 litres in 30 min, thus increasing the chance of
isolating the CTCs [68]. This platform comes into contact with a larger volume of blood compared
with the standard 7.5 mL blood volumes, but it is significantly more invasive.
4.1.3. Antibody-Coated Particles Capture Platform
Immunomagnetic bead separation is another popular method for CTC selection. Micro-sized
magnetic beads are modified with antibodies that target the surface antigens of CTCs, providing a high
detection sensitivity of tumor cells, without the necessary surface modification onto the large surface
of a microfluidic channel. In one way, the magnetic beads label the tumor cells by an immune affinity
reaction, giving the targeted cells the ability to move under magnetic fields at the next step of magnetic
separation. The second way that this method performs is to increase the cell diameter by binding the
beads to the cell surface, for the purpose of achieving a higher recovery and purity than the simple
filtration separation method [69–71]. It total, samples need to be pre-treated with antibodies that are
coated with magnetic beads, in order to utilize these immunomagnetic cell separation methods.
CellSearch is still the gold standard for CTC enrichment. It is the first and only clinically
validated, FDA-approved blood test for detecting CTCs in cancer patients of metastatic breast, prostate,
and colorectal cancer [21]. In brief, ferrofluid nanoparticles coated with antibodies are added to blood
samples to enrich for EpCAM-positive CTCs. The CTCs labelled by ferrofluid nanoparticles are then
isolated magnetically from the bulk of other cell types in the blood. After CTC isolation, the cells are
stained with a pan-cytokeratin, which is a specific marker to identify epithelial CTCs, CD45, which is
a specific leukocyte marker to identify any leukocytes that may contaminate the CTC samples and
DAPI, a DNA stain to highlight the nuclei of both the CTCs and leukocytes. Before imaging, the cells
are put in a magnet cartridge, which will force the cells to form a single focal layer for better imaging
results. The fluorescence staining and bright field results of the harvested cells are reviewed, and the
CTCs are defined based on their morphology features and staining profiles, which are cytokeratin
positive, CD45 negative, and DAPI positive, with a high nuclear to cytoplasmic ratio and a minimum
4 µm × 4 µm diameter [72].
The clinical utility of the CellSearch platform has been validated in many studies [73]. The CTCs
number above or below a predetermined threshold can predict the patient prognosis, indicating
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a favourable or unfavourable prognosis for metastatic breast, prostate, and colorectal cancers
patients [21]. For metastasis breast cancer, the patients with a cut-off value of less than five CTCs
have a remarkably longer progression free survival [74]. The comprehensive analysis of determining
the correlation between the disease progression and the CTC numbers in metastasis prostate and
colorectal cancers also demonstrates the clinical utility of CTC, with a cut-off value at five and three
CTCs, respectively [75,76].
IsoFlux from Fluxion Biosciences (Alameda, CA, USA) is an automated system that utilizes the
microfluidic and immunomagnetic strategy for CTC enrichment. The samples are pushed into the
isolation region at a lower speed, to generate a desired reaction time within the isolation region. In the
isolation region, a removable, low adherence polymer disk is place below a magnet. A high magnetic
field attracts the CTCs labelled with anti-EpCAM coated magnetic beads to reach the polymer disk
on the roof. The unbound cells continue flowing through the microfluidic channel to the waste well
(Figure 2c) [77,78]. IsoFlux displays higher sensitivity in the identification of CTCs from hepatocellular
carcinoma patients, with a detection rate of 4.7% (1/21) by the CellSearch system, and 90.5% (19/21)
by the IsoFlux method [79]. The results obtained by both systems are not consistent for the CTC study
in hepatocellular carcinoma patients.
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four generations. Reprinted with permission from the authors of [63]; (b) Schematic of the CTC-iChip.
The schematic f the w rkflow begins from the red blood cell filtr tion, inertial focusing of CTCs,
and white blood cells, followed by the removal of white blood cells under a magnetic field. Reprinted
with permission from the authors of [16]; (c) The schematic of the microfluidic flow channel of the
IsoFlux system. The blood sample mixed with magnetic particles flows through the cartridge, and the
circulating tumor cells or other rate cells are riched nd ready for molecular analysis. Reprinted
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outer edge. Reprinted with permission from the authors of [62].
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4.2. Negative Seletion of CTCs
As the understanding of the tumor heterogeneity has grown in recent years, researchers have
found out that tumors develop as complex heterogeneous tissue, rather than as one particular clone [80].
Even within the cancer cell lines, the concentration of the surface antigens may vary from cell to cell [81].
Moreover, the utilization of positive selection requires research of the surface markers, which are
expressed ubiquitously across all of the CTCs. This makes it impractical to discover unknown CTC
subtypes using positive selection.
Negative selection is widely conducted by applying CD45 antibody-immobilized microfluidic
channels. For the purpose of increasing the interaction between the leukocytes and the channel
surface, rough and unflat surfaces of microfluidic channels are made using strong acid etching or
lithography. An example is the CTC-iChip platform. This platform consists of three parts of microfluidic
components, namely, deterministic lateral displacement (DLD), inertial focusing, and magnetophoresis
to deplete the blood leukocytes. The CTCs from the blood samples of the cancer patients of non-small
cell lung cancer, prostate cancer, breast cancer, and melanoma have been successfully isolated through
this CTC-iChip platform (Figure 2b) [35]. Unlike other CTC isolation platforms, the CTC-iChip
enables whole blood as an input sample by using a micropillar array, which gradually separates the
nucleated cells from the red blood cell and platelets by deterministic lateral displacement size-based
sorting. After the hydrodynamic sorting, the remaining cells reach a single cell line arrangement
under an inertial focusing step. Under a magnetic field, this platform can either enrich the EpCAM
positive labelled CTCs or deplete the CD45 positive leukocytes. A combination of inertial focusing
and magnetic separation contributes to the precise concentration of CTC or leukocytes into product or
waste collection wells, and also allows for positive-labelled CTC enumeration or the negative depletion
of leukocytes for antigen-independent CTC enumeration.
4.3. Label-Free Separation of CTCs
4.3.1. Size-Based Filtration
The size based sorting of cancer cells can be performed as a result of the morphologic differences
between cancer cells and normal blood cells. CTC capture using microfluidics typically captures
CTCs (17–52 µm) that are larger than white blood cells (7–15 µm) and red blood cells (6–8 µm).
The CTCs are believed to be inherently larger than the other blood components. Therefore, size-based
filtration technologies have been developed for the CTC isolation strategy (Figure 3a,b) [82,83]. VyCap
microsieves are fabricated using silicon nitride, with evenly distributed pores of a 5 µm size, in a
filter surface of 8 mm × 8 mm, offering 150,000 pores for the rapid blood sample process [84]. For the
CTC clusters isolation, the next generation of CTC-chip was designed to provide an easier and more
effective isolation effect than the original chip. The two stages of the deterministic lateral displacement
strategies that were applied in this chip extract the larger and smaller cluster, maintaining about a 99%
recovery rate and over 87% of the cell viabilities [85].
Whilst this works in body fluids such as blood, others, such as urine, can be challenging.
For example, malignant urothelial cells that have a cell diameter of 10–436 µm can overlap with
exfoliated normal urothelial cells (20–100 µm). Therefore, a combination technologies may need to be
used to overcome these challenges, which include a combination of protein expressions [86].
4.3.2. Density-Based Separation
Density-based CTC enrichment is a standardized method for blood component separation.
By adding blood above the density gradient reagent and afterwards centrifugation, the blood can
be separated into the plasma layer, buffy coat layer containing mononuclear cells, and bottom layer
containing red blood cells [87]. This can be used as an initial enrichment step for the CTC isolation and
CTC identification through immune-fluorescence staining. However, this CTC enrichment method
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suffers from a poor retrieval rate and CTC purity. Modifications have been made to improve the
performance of this method on CTC isolation [88].
4.3.3. Hydrodynamic-Based Separation
Inertial force, one of the hydrodynamic-based methods, has been shown high throughput
separation efficiency, based on particle size variation (Figure 3e) [69]. There are also two types of
microchannels for inertial force-based separation, straight channels and curved channels. In the straight
channel, the fluid generates lateral forces causing transverse inertial migration of cells. When cells
flow though the channels, they need to reach equilibrium at a defined distance between the center of
the cell and the microchannel wall under the lateral forces. Larger cells are pushed toward a vortex in
the reservoir and trapped inside, while the small size cells will be flushed along the channel, toward
the outlet [89]. A spiral microfluidic channel is provided to achieve the separation of CTCs in a curved
channel scenario. While the cells flow though the microchannel, the dominant inertial force and
rotational flow will force the small size particles to move toward the direction of the outer wall of
the channel, and the large size particles migrate toward the inner wall of the channel (Figure 3d) [90].
Thus, this perpendicular Dean-flow can be conducted to separate the cells with a short processing time
and high sensitivity.
4.3.4. Acoustic Separation
Peng Li et al. developed an acoustic cell separation device that can manipulate thousands
of cells, separating the tumor cells from the blood cells, based on their significant difference in size,
compressibility, and other physical properties, by exposing them to sound waves while flowing through
the microchannel (Figure 3c) [91]. It can offer a unique approach for researchers in bioengineering
projects and clinical diagnosis. Separating the cells with sound offers a gentler alternative to the
existing cell sorting techniques, which requires the labelling cells with antibodies or exposing them
to stronger mechanical forces that may damage the cells. While there are some white blood cells
that have overlapping acoustic properties with cancer cells, a platform, which utilizes the negative
acoustic contrast elastomeric particles with CD45-binding whole blood cell (WBCs), was developed
to further reduce the WBCs’ background [92]. This platform uses an integration of three modules of
microfluidic platforms, which consist of a high-throughput separation, cell spatial organization and
cell staining, imaging, and quantification analysis. This platform combines the isolation and evaluation
steps towards rare cancer cell sorting and identification. These streamlined functions could be easily
extended to various applications on a single cell biology [93].
4.3.5. Magnetophoresis Separation
Magnetophoresis applies the paramagnetic properties of erythrocytes and the diamagnetic
properties of other cells, such as leukocyte and tumor cells. In this case, the erythrocytes and biological
components could be migrated from the sample under the external magnetic field force. A continuous
paramagnetic capture mode of the magnetophoretic microseparator was firstly utilized for the isolation
of the suspended breast cancer cells from peripheral blood, based on the native magnetic properties of
blood cells, without adding magnetic beads and probes [54]. The remaining nucleated cells, including
white blood cells and spiked cancer cells, are detected by a micro-electrical impedance spectroscopy
system. It showed that 94.8% of the breast cancer cells from the spiked blood samples were separated
and detected.
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Figure 3. Label-free CTC isolation method. (a) Illustration of microfluidic cell sorter. A physical barrier
is located, as shown, to separate the cells by size difference. Small cells pass through the gap under
the barrier and are collected at outlet 2, wh le the large cancer cells move along the b rrier and are
collected at another outlet. Reprinted with permission from the authors of [83]; (b) Schematic of the
multi-obstacle architecture microfiltration chip for CTC separation. The size gradient filter chip has
two filter gaps and the cells are captured between the two filter gaps. Reprinted with permission
from the authors of [82]; (c) Schematic of acoustic tweezers for isolating circulating tumor cells from a
blood sample. These yellow tilted transducers generate soundwaves to move the cells as they pass
through the d vice. The tumor cells are separated from the blood cells b sed on the difference in size
and compressib lity. Repri ted with permiss on from the authors of [91]; (d) The principle of CTC
enrichment by a spiral channel. The CTCs are focused near the inner wall because of the combination of
the inertial lift force and the Dean force, while the white blood cells are focused closer to the outer wall.
Reprinted with permission from the authors of [94]; (e) Illustration of VTX-1 CTC isolation platform.
A blood sample flows through the microchannels and the laminar microscale vortices trap the cells
based on th ir size, shape, and deformability. Reprinted with permission from the authors of [95].
4.3.6. Dielectrophoresis Separation
When one cell is under the inhomogeneous electric field, it becomes polarized. The polarization
interacts with the applied electric field, making each kind of cell perform a unique electrical force,
because of the different properties of the cell membrane, cell size, and cell cytoplasmic. When it comes
to CTCs, if the electrophoretic of the CTCs are more polarizable than other cells and the medium,
then they will migrate towards the electrode side, resulting in separating themselves from the rest of
the normal blood cells [96].
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5. Exosome Separation and Analysis
Exosomes are cell-derived vesicles that carry cell specific protein, lipids, and nucleic acids,
that circulate within the body fluids. The cargo that exosomes carry allows for investigation into the
tumor origin and potential disease progression. Whilst promising, the translational applications of
the exosomes are still a challenge as there are non-standard protocols for the exosome separation
and analysis. Despite the conventional exosome separation methods of the ultra-centrifugation and
density gradient, the microfluidic methods offer a novel direction for the exosome research area with
its less reagent cost, quick processing time, downstream analysis integration ability, and output sample
integrity [97]. The size difference and surface biomarkers are two classic factors to isolate the exosomes
from the background samples. Thus, the microfluidic platforms for exosome isolation also spits into
two streams, namely size-based methods and immuno-affinity-based methods.
5.1. Immuno-Affinity Based Separation and Analysis
Similar to the separation method in the CTCs, the immuno-affinity-based exosomes’
isolation and analysis can be achieved by modifying the microchannel channel surface or using
antibodies-conjugated microbeads. For the former method, the anti-CD63 antibody was coated onto
the surface of the microfluidic channel for capturing exosomes [98]. Then, various antibodies targeting
the exosomes’ surface biomarkers are functioned onto the surfaces of different microfluidic devices.
However, limited by the surface area of the antibodies immobilization, the efficiency of exosome
capture reaches a bottleneck. Therefore, immunomagnetic beads are introduced to overcome this
problem. While mixed with exosome samples, the magnetic beads and exosome compound can
be considered as a composite in the subsequent magnetic manipulation. The amount of magnetic
beads represent the amount of the exosome, thus making the exosome quantitation and analysis
possible (Figure 4a) [51]. The immunomagnetic bead method enables an easy sample preparation and
rapid exosome enrichment, thus contributing to a higher sensitivity and capture efficiency. To achieve
the goal of integrating the exosome integration and chemical lysis, protein immunoprecipitation,
and chemiluminescent reactions, a microfluidic chip is developed to capture and analyze the circulating
exosome in the plasma [99]. The reported recovery yield of the exosomes using immuno-affinity
functionalized CD63 with herringbones groves has been reported to be between 42% and 94% [52].
Other immune-affinity microfluidic technologies include the ExoChip (functionalized CD63 in a
mulit-chamber device and nPLEX [functionalized CD24, CD63, and EpCAM] gold surface with
nanohole arrays), RInSE (inertial solution exchange for continuous isolation of affinity capture
[EpCAM] microbeads), iMER (isolation using magnetic microbeads [EGFR]), ExoSearch (capture
of CD9 microbeads), Nano-IMEX (capture of Y-shaped microposts with CD81nanostructured coating),
functionalized CD9/CD63 gold surfaces, and µMED (positive and negative enrichment with
microbeads of different sizes capturing CD63 particles).
5.2. Size-Based Exosomes Separation and Analysis
Isolating exosomes by size-based microfluidic systems mostly relies on the nanoporous structure
systems. One classical size-based demonstration is that the nanowire spacing on the micropillars
are fabricated to create a high density of physical trapper exosomes [100]. The micropillars shown
here work as a scaffold of nanowires, and filter out the large-sized blood cells and other sample
components during the exosome separation process. This fabricated microfluidic device selectively
traps the exosomes with diameter of 40–100 nm, and filters out proteins, other vesicles, and cell
debris at the same time. Moreover, the trapped exosomes remained intact by dissolving into the
buffer when compared to the ultracentrifugation methods (Figure 4b) [100]. Novel particle soring
techniques are also introduced in the exosome isolation area. An acoustic nanofilter using ultrasound
to separate particular particle samples is used, based on their size and density difference. Larger
particles experience a stronger radiation force and migrate faster towards the pressure nodes, while the
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smaller particles remain in the main channel [101]. A novel centrifugal platform utilizes a gentle and
efficient size-based exosome separation method without using a syringe pump and other equipment.
Combing with table top centrifuge, the extraction of exosome can be achieved in eight minutes, with
high separation efficiency of 90% [102].
5.3. Other Technologies for Exosome Isolation
Membrane filtration technologies can be used, such as pressure driven filtration using
micro/nano-engineered filters [103,104], electrophoresis driven filtration, double filtration (e.g.,
Exodisc), or nanoporous membranes, which allow for the capture of exosomes [105,106]. Acoustic
separation is possible using continuous contact-free nanofilters. For the isolation of urine derived
exosomes, the deterministic lateral displacement sorting (NanoDLD) using an array of pillars is
possible, and the utilization of inertial focusing using viscoelastic fluid has been also reported [107].
6. Circulating Tumor DNA Separation and Analysis
The analysis of ctDNA provides researchers with a further understanding of the basic biological
process, prenatal status, and cancer development and progression [108,109]. ctDNA have demonstrated
utility in monitoring disease progression over the course of therapy and in the detection of minimal
residual disease.
In the conventional methods, electrophoretic and fluorescence signal detection are widely
used in DNA analysis. However, inherent limitations, such as the high cost and sample loss,
are unavoidable during the multiple sample treatment progress. Therefore, microfluidic devices with
integrated functionalities, such as sample preparation, purification, and product analysis, are needed.
DNA molecules can be labeled with fluorescent dyes and can be detected with a high signal to noise
ratio. Microfluidic platforms for separating nucleic acid have been conducted by many methods, such as
silica-based surfaces, functionalized paramagnetic beads, oligonucleotide-modified polymer surfaces,
pH-dependent charged surfaces, Al2O3 membranes, and liquid-phase isolation [110]. However,
the processing of reaction products is typically not finished on the microfluidic platform.
One advantage of the microfluidic systems is the ability to combine various techniques into
a single integrated and streamlined design (Figure 4c) [111,112]. For example, a highly integrated
single molecule DNA analysis platform demonstrated that the polymerase chain reaction (PCR)
amplification of a single DNA template is possible, followed by the capillary electrophoretic analysis
of the products. The PCR reactions performed in nanoliter chambers can be completed in as fast as 30 s.
The fluorescent dye labeled PCR products are then directly injected into the gel-filled capillary channel
for electrophoretic analysis [113]. Techniques such as BEAMing (beads, emulsion, amplification,
and magnetics) technology incorporate microfluidics to separate the template molecules into individual
reaction vessels by separating the sample and PCR reagents into oil droplet emulsions, or by combing
the emulsion PCR to generate even sized droplets. BEAMing was one of the first technologies that
allowed for the quantitative sensitive interrogation of mutant ctDNA [114]. Digital PCR techniques
utilize the limiting dilution of DNA into individual PCR reactions, of which there are two main
methods for partitioning individual reactions, namely nanofluidics for well based partitioning and
microdroplet partitioning using water-in-oil emulsion. Examples for nanofluidics are the Fluidigm and
ThermoFisher OpenArray, and the microdroplet examples are the RainDance and Biorad platforms.
These technologies are more precise and demonstrate a linear response to the number of DNA copies,
eliminating the need for standard curves to be performed, and enables the use of digital PCR for high
resolution determination of the copy number variations (CNVs) [115].
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7. Microfluidic Techniques in CAR-T Cell Therapy
Immunotherapy has emerged as important treatment option for canc r. Chimeric antigen
receptor (CAR) T cell therapy works using a method of gen tically modifying the patient’s own T
cells, so that the T cells can recognize and kill the cancer cells without damaging the normal healthy
cells. In 2017, there were two CAR-T cell therapies that were approved by the FDA, one for the
treatment of children with acute lymphoblastic leukemia, and the other for adults with advanced
lymphomas. Moreover, different forms of CAR-T cell therapies are still being developed, including
those for solid tumors. However, the current state of engineering the T cells is quite expensive and
time-consuming, requiring multiple incubati n technologies and highly skilled technicians. To solve
these problems, communi es rom biology and engineering disciplines are working together to develop
microfluidic platforms to accelerate this process. Glulia et al. discussed how the 3D microfluidic tumor
models mimic the tumor environment, to assess the engineered T cells and improve the therapeutic
efficacy [116]. Researchers at Draper are now developing new microfluidic platforms that are able to
promote the cell therapies. The first step of this approach is using the acoustics microfluidic platform
to enrich the T cells from a patient’s blood sample, achieving rapid and automated T cells separation.
After T cells enrichment, the microfluidic chip improves the efficiency of transferring the genetic
material into T cells, by educ ng the amount of the transferring vector and decreasing the amount
of time. This has led to standardization, minimizing the human error and risks associated with cross
contamination [117].
8. Challenges and Perspectives
Microfluidic technologies will serve an important role in the field of cancer research as well
as progressing personalized medicine. In the field of non-invasive liquid biopsy research, CTCs,
exosomes, and circulating tumor nucleic acids are used as biomarkers of the minimum residual disease
for the monitoring of disease. As a result of different sources and characteristics of these biomarkers,
the separation and detection method varies among samples, which leads to inherent strength and
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limitations, in turn (Table 1). Many studies have validated the potential of microfluidics in biomarkers’
detection, separation, and characterization. Although microfluidic technology shows promise, there are
still hurdles to overcome prior to translation into clinic.
CTCs provide the units of metastatic diseases that can be sampled non-invasively by a blood draw.
Therefore, the isolation and characterization of CTCs is critical in order to understand the underlying
mechanism involved in metastasis. Microfluidic CTC enrichment is categorized into two main streams,
label-free techniques and immune-affinity techniques. The ideal microfluidic platform allows for a
high CTC recovery rate, high sample throughout volume, and short experimental time.
One appealing advantage of the microfluidic separation techniques is that the high volume and
parallel throughout are compatible with the high sample flow rate. Larger sample volumes and higher
flow rates make innovative tumor diagnostic methods and therapeutic applications possible [118].
In the case of CTCs, most of the analysis is performed using 7.5 mL of blood. However, recent studies
have shown that it is necessary to process larger volumes of blood in order to collect sufficient CTC
numbers for reliable enumeration and genomic analysis. Therefore, the microfluidic platforms are ideal
to handle and analyze small numbers of cells within large volumes of raw samples. As mentioned
above, there are two major types of immuno-affinity-based separation methods, namely positive
selection and negative selection. Both are based on either the modification of the microfluidic channels
or on the application of antibodies-conjugated to micro-sized magnetic particles. The performance of
antibody-modified channels is limited by the interactions between the surface-bound antibodies and
the target cells flowing through. The negative selection-based methods allow for a greater capture of
the CTC subpopulations, and in so doing, a greater heterogeneity of CTCs than the positive selection
methodologies. Whilst there have been developments, there remains a need for improved CTC
separation efficiencies for downstream analysis. One method has investigated the surface chemistry
of microparticles to provide a short processing time and high CTC recovery rate. Another method
utilizes a combination of multiple cell capture technique components, combined into one platform in
order to improve the CTC capture performance.
The separation and analysis of the exosome on microfluidic systems may outperform traditional
methods, such as ultracentrifugation and some commercially available exosome isolation kits.
However, the release of the exosomes of differential sizes and concentrations makes isolating and
analysis challenging. The existing exosome microfluidic systems mostly rely on size difference and
immuno-affinity techniques. For the former method, the performance of the exosome isolation is
greatly affected by the size difference of the secreted exosomes.
In addition, unlike the CTCs, which are of a micro meter size, exosomes are of nanometer size
and thereby require more advanced technologies for the device fabrication. Generally, immuno-
affinity-based separation methods have a high specificity and sensitivity. However, because of the
heterogeneity of the exosomes, there is no common biomarker that can distinguish all of the cancer
secreted exosomes from the normal exosomes.
The utility of ctDNA has been shown in identifying minimal residual disease and in the tracking
of mutations during therapy. Through the integration of nucleic acid separation, and the analysis
on microfluidic systems, these novel platforms show advantages such as low cost, fast processing
time, and less contamination, compared with conventional methods. However, there are still some
improvements for nucleic acid separation and analysis platforms. Most types of nucleic acid are
collected by an extraction process, which will cause damage to the sample integrity. In terms of the
circulating nucleic acid separation, there is no standard sample collection and processing protocol,
thus limiting the development of reliable and efficient microfluidic platforms.
Overall, the first question comes down to the intrinsic rarity and heterogeneity of the circulating
tumor markers. To solve this problem, complexed analysis platforms that combine physical and
biological properties of tumor biomarkers need to be developed. Secondly, researchers need to
establish the relationship between microfluidic technology and the analysis of the circulating
biomarkers. There are a number of liquid biopsy tests that have been approved by FDA so far,
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such as the breakthrough device from the Foundation Medicine company, approved at 2018; the cobas
EGFR mutation test v2, approved for NSCLC in 2017; myRisk, approved for breast cancer in
2014 [119–121]. However, these tests mentioned above are based on ctDNA sequencing from plasma
samples. Although there are many microfluidic-based liquid biopsy platforms that have shown appealing
results, the CellSearch system remains the only FDA-approved CTC platform as of January 2018. To gain
more attention from the medical society and to accelerate the FDA approval progress, more validation
tests regarding the specificity, sensitivity, and reproducibility of the microfluidic platforms need
to be determined for each tumor type, as well as among large populations on current and future
microfluidic systems.
Table 1. Comparison of three liquid biopsy methods (circulating tumor cells [CTCs], circulating tumor
DNA [ctDNA], and exosomes).
Types of Liquid
Biopsy Samples Circulating Tumor Cells ctDNA Exosomes
Sample Sources Peripheral Blood Plasma or Serum Plasma or Other Body Fluids
Separation or
detection methods
Positive selection by antibody coated
microstructure and microparticles




Negative selection by antibody coated
microstructure and microparticles Label-free methods: Size
based nanowire capture,
acoustic nanofilter




High specificity of tumor-derived High sensitivity Samples available invarious body fluids
Approved by FDA clinical practice
Ongoing clinical trials for
treatment suggestions
DNA, RNA, and protein
could all be investigated
DNA, RNA, and protein could all be
investigated Functional studies available
Functional studies available
Limitations
Loss of heterogeneity on non-label free
isolation methods
No RNA or protein could be
investigated
Loss of heterogeneity on
non-label free isolation
methods
Instability of tumor diagnosis at early stage
Tumor specific mutations are
hard to distinguish due to
redundant background noise signals
Absence of specific tumor
derived markers
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